Investing.com - BridgeBio Pharma (NASDAQ: BBIO) reported first quarter EPS of $-0.20, $0.72 better than the analyst estimate of $-0.92. Revenue for the quarter came in at $211.12M versus the consensus estimate of $7.26M.
BridgeBio Pharma's stock price closed at $27.03. It is down -20.29% in the last 3 months and up 86.18% in the last 12 months.
BridgeBio Pharma saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See BridgeBio Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, BridgeBio Pharma's Financial Health score is "weak performance".
Check out BridgeBio Pharma's recent earnings performance, and BridgeBio Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar